NEREUS (tradipitant)
NEREUS is indicated for the prevention of vomiting induced by motion in adults.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2025-12-30
- Patent Cliff
- 2036
- Routes
- ORAL
- Dosage Forms
- CAPSULE
NEREUS Approval History
What NEREUS Treats
1 FDA approvalsOriginally approved for its first indication in 2025 .
- Other (1)
Clinical Trial Registry
15 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT07446439 | VP-VLY-686-3601 | Ph 3 | recruiting | A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use |
| NCT06138613 | VP-VLY-686-3403 | Ph 3 | active not recruiting | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness |
| NCT05653310 | 21-012527 | Ph 2 | enrolling by invitation | Tradipitant for Functional Dyspepsia |
| NCT06804603 | VP-VLY-686-2601 | Ph 2 | completed | A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use |
| NCT04028492 | VP-VLY-686-3301 | Ph 3 | completed | Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis |
| NCT03772340 results posted | VP-VLY-686-2401 | Ph 2 | completed | Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness |
| NCT05903924 results posted | VP-VLY-686-3404 | Ph 3 | completed | Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness |
| NCT06836557 | VP-VLY-686-3304 | Ph 3 | recruiting | Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis |
| NCT04327661 results posted | VP-VLY-686-3401 | Ph 3 | completed | Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness |
| NCT02651714 results posted | VP-VLY-686-2102 | Ph 2 | completed | Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis |
| NCT04140695 results posted | VP-VLY-686-3102 EPIONE2 | Ph 3 | terminated | Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2) |
| NCT03568331 results posted | VP-VLY-686-3101 EPIONE | Ph 3 | completed | Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE) |
| NCT04849559 results posted | VP-VLY-686-1301 | Ph 1, Ph 2 | completed | Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers |
| NCT04326426 | VLY-686-3501 | Ph 3 | enrolling by invitation | ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection |
| NCT02621385 | VP-VLY-686-1102 | Ph 1 | completed | Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy Subjects |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
NEREUS FDA Label Details
Indications & Usage
FDA Label (PDF)NEREUS is indicated for the prevention of vomiting induced by motion in adults. NEREUS is a substance P/neurokinin 1 (NK1) receptor antagonist indicated for the prevention of vomiting induced by motion in adults.
NEREUS Patents & Exclusivity
Patents (4 active)
Exclusivity
Pro Intelligence Preview
Deep insights for NEREUS
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2036
- • 4 active patents
Trial Analysis
- • 15 total trials
- • Stage: Expansion
Competitive Landscape
- • Competitor tracking
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment